Clinical Trials Logo

Filter by:
NCT ID: NCT02095899 Withdrawn - Pain Clinical Trials

Effect of Rufinamide on Chronic Postthoracotomy Pain Syndrome

RUFPTPS
Start date: March 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test if rufinamide has an effect on chronic neuropathic pain in patients with a post thoracotomy pain syndrome.

NCT ID: NCT02085668 Withdrawn - Clinical trials for Chronic Heart Failure

Renal Denervation in Patients With Chronic Heart Failure

Start date: May 2014
Phase: N/A
Study type: Interventional

The purpose of the trial is to investigate the safety and effectiveness of renal denervation for the treatment of chronic heart failure (CHF).

NCT ID: NCT02070887 Withdrawn - Parkinson's Disease Clinical Trials

Inhibiting COMT in Parkinson's Disease

Start date: February 2014
Phase:
Study type: Observational

The overall aim of this observational study is to investigate the impact of COMT inhibition on homocysteine metabolism, vascular physiology and correlates of neurodegeneration in PD patients with certain COMT genotype. It is designed to evaluate effect size of Hcy lowering to secondary outcome parameters. Assessment of outcome parameters will be rater-blinded or computer-based.

NCT ID: NCT02053311 Withdrawn - Prostate Cancer Clinical Trials

Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents

Start date: August 19, 2014
Phase: Phase 3
Study type: Interventional

The main object of this multicenter, randomized, double-blind, placebo-controlled phase III trial is to assess impact of maintenance of orteronel on disease progression and hence on quality of life of patients with metastatic castration resistant prostate cancer pretreated with novel hormonal agents who have non-progressive disease after chemotherapy with a taxane.

NCT ID: NCT02011178 Withdrawn - Clinical trials for Diabetic Kidney Disease

Prevention of Microvascular Complications in Overweight Diabetics With Surgery or Best Medicine

PROMISE
Start date: March 2014
Phase: N/A
Study type: Interventional

Background: Diabetic kidney disease (DKD) is chronic and often progresses to kidney failure,heart disease and premature death. Unfortunately, the best medical therapies available for DKD today are ultimately unable to prevent its progression, especially in obese patients.Surgical rerouting of food within the gut with a gastric bypass operation (RYGB), improves diabetes and some of its complications. The investigators propose to investigate whether RYGB in combination with best medical therapy in patients with DKD and obesity prevent further deterioration of kidney function over a 3 years follow up period. Study design: This is an international collaboration with leading centres in Sweden and Switzerland in which100 obese type 2 diabetic patients with established DKD will volunteer to be randomly assigned to receive best medical therapy with RYGB or best medical therapy without surgery. Participants will be 18-65 years with type 2 diabetes and impaired kidney function. Yearly measurements of kidney function will then be done over a period of 3 years as a primary outcome to determine whether differences in DKD can be detectable. The study will also examine and compare a) safety of the interventions, b) the health economic impact on direct healthcare costs and Quality of Life in patients as well as c) the value of a new marker of DKD in determining which patients are most likely to benefit from surgery. Overall the study will strengthen the evidence base guiding clinical decisions about the usefulness of RYGB as an add on therapy to best medical therapy in stopping progressive DKD in patients with obesity and diabetes.

NCT ID: NCT01973504 Withdrawn - Trauma Clinical Trials

Phase 2c Dose Comparison Study of MP4OX in Trauma

Start date: December 2013
Phase: Phase 2
Study type: Interventional

MP4OX is being developed as an ischemic rescue therapy to perfuse and oxygenate tissues at risk during hemorrhagic shock. MP4OX is a pegylated hemoglobin-based colloid designed to improve perfusion and target delivery of oxygen to ischemic tissues. This study will evaluate safety and efficacy of MP4OX treatment, in addition to standard therapy, in trauma patients suffering from lactic acidosis due to severe hemorrhagic shock.

NCT ID: NCT01964235 Withdrawn - Clinical trials for Advanced Hepatocellular Carcinoma

Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma

Start date: December 2016
Phase: Phase 2
Study type: Interventional

This study is establish whether INC280 is safe and has beneficial effects in patients with advanced hepatocellular carcinoma known to have dysregulation of c-MET pathway and whose disease progressed while on, or after, treatment with sorafenib or who are intolerant to sorafenib. Patients will be randomized in a 2:1 ratio to receive INC280 at 600mg BID plus best supportive care (BSC) or placebo plus BSC, until disease progression or intolerable to study treatment. Patients treated with placebo plus BSC will have the opportunity to receive INC280 treatment upon documented further disease progression (RECIST 1.1) per investigator's discretion after unblinding. Patient will be stratified to geographical region (Asia vs Rest of World ) and tumor burden (present macroscopic vascular invasion and/or extra-hepatic spread vs not present).

NCT ID: NCT01879566 Withdrawn - Clinical trials for Therapy-resistant Hypertension and Sleep Apnea

Effect of Catheter-based Radiofrequency Ablation Therapy in Patient With Therapy-resistant Hypertension and Sleep Apnea Syndrome

Start date: May 2013
Phase: N/A
Study type: Observational

The aim of this prospective single-center study is to evaluate sympathetic nervous system directly measured by microneurography, 24-hour blood pressure, endothelial function, vascular compliance, quality of life and platelet adhesion in patients with sleep apnea syndrome (defined by a complaint of excessive daytime sleepiness, an Epworth sleepiness score>8[10], and an apnea/hypopnea index (AHI>15/h) before and after catheter-based radiofrequency ablation of renal nerve. If the selected patients are treated with CPAP, this therapy should be stable during the whole study time. Primary and secondary end-point will be measured before and 1, 3, 6 and 12 months after renal sympathetic denervation.

NCT ID: NCT01848431 Withdrawn - Tumor Clinical Trials

Randomized Study on the Effects of Moderate Anaemia in Free Microvascular Tissue Transfer

Start date: May 2013
Phase:
Study type: Observational

The evaluation of Perfusion of free flaps in patients with moderate anaemia and possible reduction of the transfusion threshold. - Trial with surgical intervention

NCT ID: NCT01795170 Withdrawn - Clinical trials for Pyridoxine Dependant Epilepsy

Neurodevelopmental Outcome of Early Dietary Lysine Restriction in Pyridoxine Dependent Epilepsy Patients

NOEL
Start date: April 2013
Phase: N/A
Study type: Observational

Restricting dietary lysine intake in infants from age 3 months or less with confirmed diagnosis of pyridoxine-dependent epilepsy due to Antiquitin (ATQ) deficiency will: reduce the accumulation of neurotoxic substratesα-aminoadipicsemialdehydeandits cyclic equivalent 1-piperideine-6-carboxylate;and will improve overall neurodevelopmental outcome at 3 years of age by acting as an effective intervention into the complex pathophysiology of the condition.